San Rafael, CA, United States of America

Colin Conrad Collins

This inventor holds 18 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent, primarily in Cancer Genomics. Top assignees: University of California, The Hospital for Sick Children, Other. Active years: 1998-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Colin Conrad Collins. Retrieved from https://idiyas.com/inventor/colin-conrad-collins

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 18 

% Patents Active = 61.1



Average Co-Inventor Count = 3.9

ph-index = 8

Forward Citations = 180(Granted Patents)


Location History:

  • San Raphael, CA (US) (2010)
  • San Rafael, CA (US) (1998 - 2015)

Company Filing History:


Years Active: 1998-2015

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
CYP24 Expression
Prostate Cancer
Breast Cancer
20q13 Amplicon
Biomarkers
End Sequence Profiling
Comparative Fluorescence Hybridization
Chromosomal Amplifications
18 patents (USPTO):Explore Patents

Title: The Innovative Mind of Colin Conrad Collins

Introduction

Colin Conrad Collins, based in San Rafael, California, is a prominent inventor known for his significant contributions to medical science and genetics. With 18 patents to his name, he has been instrumental in advancing our understanding of genetic markers and their implications in disease treatment and prevention.

Latest Patents

Among his latest inventions, Collins has made groundbreaking advancements with the following patents:

1. **Genes from 20q13 amplicon and their uses** - This invention relates to cDNA sequences derived from a region of amplification on chromosome 20, which are associated with various diseases. These sequences are applicable in hybridization methods designed to identify chromosomal abnormalities and can be utilized in treatments for these conditions.

2. **Detecting CYP24 expression level as a marker for predisposition to cancer** - Collins discovered that an amplification of the CYP24 gene or an increase in its activity can indicate a predisposition to certain cancers, such as breast cancer. His methods involve detecting CYP24 levels in biological samples, enabling early diagnosis and intervention.

Career Highlights

Colin Collins has collaborated with respected institutions such as the University of California and The Hospital for Sick Children. His role in these organizations has allowed him to develop and market innovative solutions in medical science, particularly in genetics and cancer research.

Collaborations

Throughout his career, Collins has worked alongside notable coworkers like Joe W. Gray and Soo-In Hwang. These collaborations have enriched his research and driven the development of his impactful inventions.

Conclusion

Colin Conrad Collins stands out as a significant figure in the world of invention and innovation, particularly within the medical field. His work on genetic markers not only aids in diagnosis and treatment but also paves the way for future research and discoveries that will benefit countless individuals. With a remarkable portfolio of patents, Collins continues to inspire upcoming inventors and medical professionals alike.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…